Arix Bioscience PLC (ARIX)
Notice of Results & Investor Presentation
03-Aug-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Arix Bioscience plc
Notice of Results & Investor Presentation
LONDON, 3 August 2022:Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, will announce its results for the six months ended 30 June 2022 on Wednesday 10 August 2022.
Analyst Briefing: 9:00am, Wednesday 10 August
Management will host a virtual analyst presentation followed by a Q&A session at 9:00am BST on Wednesday 10 August. Analysts wishing to join should register their interest by contacting [email protected].
Investor Presentation: 2:00pm, Wednesday 10 August
Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 2:00pm BST on Wednesday 10 August.
The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the 'Investor Meet Company' dashboard up until 9:00 a.m. on Wednesday 10 August or at any time during the live presentation.Investors can sign up to Investor Meet Company for free via:https://www.investormeetcompany.com/arix-bioscience-plc/register-investor
Investors who already follow Arix on the Investor Meet Company platform will automatically receive an invitation to the event.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod,Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
| ISIN: | GB00BD045071 |
| Category Code: | NOR |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 178861 |
| EQS News ID: | 1411893 |
| End of Announcement | EQS News Service |
==